Evotec, BMS debut program to speed academic translational research

By The Science Advisory Board staff writers

May 7, 2021 -- Evotec announced on May 6 a new program that aims to accelerate translational research from the U.K.'s academic life science ecosystem in collaboration with Bristol-Myers Squibb (BMS).

The company launched beLab1407, a new $20 million program to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the U.K.'s top-tier academic institutions.

The program aims to advance innovation in therapeutics from academia to patient benefit, as well as creating spinout companies in the process.

If you like this content, please share it with a colleague!

Related Reading

Evotec begins construction on Toulouse biologics manufacturing facility
Evotec will soon break ground on its first commercial biologics manufacturing facility in Europe at its Campus Curie in Toulouse, France.

Evotec, Takeda partner on RNA-targeting drug discovery, development
Evotec has entered into an alliance with Takeda Pharmaceutical with the goal of discovering and developing RNA-targeting small-molecule therapeutics for...

Eveotec, Indivumed partner on novel lung cancer therapies
Evotec and Indivumed announced on January 23 a partnership to collaborate on drug discovery and development of novel therapies for non-small cell lung...

Evotec, Bayer partner for drug discovery in women's health
Evotec and Bayer announced on January 9 the expansion of their partnership in women's health with a new five-year, multitarget collaboration with participation...

MilliporeSigma licenses CRISPR IP to Evotec
MilliporeSigma announced today that it signed a license agreement providing Evotec SE access to MilliporeSignma's foundational CRISPR intellectual protect....